March 7, 2011

7:30 Registration / Continental Breakfast

8:00 Chairperson's Opening Remarks

8:10 Neuropharmacology for Acute Brain Injury: Current Treatment Regimens and Unmet Needs

Darryl Kaelin, M.D.
Medical Director, Acquired Brain Injury Program
Shepherd Center

8:45 Injury-Specific Treatment Strategies for Traumatic Brain Injury

Ramesh Raghupathi, Ph.D.
Associate Professor, Department of Neurobiology & Anatomy
Drexel University College of Medicine

9:20 Military Neuroprotection Translation Research: Bench to Bedside with the INTREPID-2566 TBI Trial

Frank C. Tortella, Ph.D.
Chief, Department of Applied Neurobiology & CCCRP Brain Trauma Program
Manager, Division of Neuropsychiatry & Neuroscience
Walter Reed Army Institute of Research

9:55 Refreshment Break

10:15 Development of a Dopaminergic Agent for Vegetative and Minimally Conscious State Patients

Neal M. Farber, Ph.D.
CEO
NeuroHealing Pharmaceuticals, Inc.

10:50 Development of a Biomarker Diagnostic Test for Traumatic Brain Injury

Jackson Streeter, M.D.
Chief Executive Officer and Chief Medical Officer
Banyan Biomarkers

11:25 Neurosteroids as Candidate Biomarkers and Novel Therapeutics in TBI and other CNS Disorders

Christine Marx, M.D.
Associate Professor, Department of Psychiatry and Behavioral Sciences
Duke University Medical Center

12:00 Luncheon

1:00 Traumatic Brain Injury Regenerative Medicine: Strategies for Assessment Through Recovery

Regina Armstrong, Ph.D.
Director
Center for Neuroscience and Regenerative Medicine
Department of Anatomy, Physiology, and Genetics
Uniformed Services University of the Health Sciences

1:35 Regenerative Recovery After Traumatic Brain Injury

Allen Davidoff, Ph.D.
Vice President Product Development
Stem Cell Therapeutics Corp.

2:10 TBI Biomarkers Research: Implications for Prognosis, Management and Therapeutic Applications

Amy K. Wagner, M.D.
Associate Professor, Physical Medicine and Rehabilitation
University of Pittsburgh

2:45 Refreshment Break

3:05 Site-specific, Sustained Release Drug Delivery for Prevention of Complications After Traumatic Brain Injury

R. Loch Macdonald, M.D., Ph.D
Keenan Endowed Chair of Neurosurgery
University of Toronto
Chief Scientific Officer
Edge Therapeutics, Inc.

3:40 End of Conference